50779-65-2

Basic information

• Product Name: 6-METHYL-BENZOFURAN-2-CARBOXYLIC ACID
• Synonyms: 6-METHYL-BENZOFURAN-2-CARBOXYLIC ACID;OTAVA-BB 1178906;6-methyl-2-benzofurancarboxylic acid
• CAS NO: 50779-65-2
• Molecular Formula: C10H8O3
• Molecular Weight: 176.17
• Mol File: 50779-65-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 326.5±22.0 °C(Predicted)
• Appearance: /
• Density: 1.303±0.06 g/cm3(Predicted)
• PKA: 3.20±0.30(Predicted)
• CAS DataBase Reference: 6-METHYL-BENZOFURAN-2-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-METHYL-BENZOFURAN-2-CARBOXYLIC ACID(50779-65-2)
• EPA Substance Registry System: 6-METHYL-BENZOFURAN-2-CARBOXYLIC ACID(50779-65-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 50779-65-2(Hazardous Substances Data)

Usage

General Description

6-Methyl-Benzofuran-2-Carboxylic Acid is a synthetic chemical compound. The term refers to its systematic name which reveals its specific structural aspects: it is a benzofuran compound that means it has a benzene ring fused to a furan ring, it contains a methyl group which is an alkyl derived from methane, and it includes a carboxylic acid functional group. It has molecular formula C10H8O3. These chemicals and its derivatives play a significant role in the manufacture of pharmaceuticals, polymers, and various organic compounds. However, there's limited published information available on the properties or widespread usage of 6-Methyl-Benzofuran-2-Carboxylic Acid specifically. Its toxicity and environmental impact are factors that would need to be evaluated as part of its risk assessment.

Upstream product

• 2445-83-2 7-methylcoumarin 
• 1210226-83-7 tert-butyl-6-methyl-benzo[b]furan-2-carboxylate 
• 13939-06-5 molybdenum hexacarbonyl 
• 1163785-15-6 ethyl 2-(2-formyl-5-methylphenoxy)acetate 
• 53715-89-2 ethyl 6-methylbenzofuran-2-carboxylate 
• 698-27-1 4-methylsalicylaldehyde 
• 685-87-0 Diethyl 2-bromomalonate 

Downstream Products

• 82788-37-2 methyl 6-methylbenzofuran-2-carboxylate 
• 26018-42-8 6-Methyl-2,3-dihydro-benzofuran-2-carboxylic acid 

Relevant articles and documents

Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site

A novel series of shikonin-benzo[b]furan derivatives were designed and synthesized as tubulin polymerization inhibitors, and their biological activities were evaluated. Most compounds revealed the comparable anti-proliferation activities against the cancer cell lines to that of shikonin and simultaneously low cytotoxicity to non-cancer cells. Among them, compound 6c displayed powerful anti-cancer activity with the IC50 value of 0.18 μM against HT29 cells, which was significantly better than that of the reference drugs shikonin and CA-4. What's more, 6c could inhibit tubulin polymerization and compete with [3H] colchicine in binding to tubulin. Further biological studies depicted that 6c can induce cell apoptosis and cell mitochondria depolarize, regulate the expression of apoptosis related proteins in HT29 cells. Besides, 6c actuated the HT29 cell cycle arrest at G2/M phase, and influenced the expression of the cell-cycle related protein. Moreover, 6c displayed potent inhibition on cell migration and tube formation that contributes to the antiangiogenesis. These results prompt us to consider 6c as a potential tubulin polymerization inhibitor and is worthy for further study.

POLYCYCLIC HERG ACTIVATORS

The present invention provides a compound of formula (I), in which R1, R2 and R3 are defined in the Summary of the Invention, or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the i

Boric acid compounds, and preparation method and use thereof

The invention relates to the fields of pharmaceutical chemistry and medicine therapeutics, concretely relates to a new boric acid compounds, and a preparation method and a use thereof, and especially relates to new substituted five-membered heterocyclic boric acid and substituted benzo five-membered boric acid compounds, and a preparation method thereof. A result of bioactive screening test of the substituted five-membered heterocyclic boric acid and substituted benzo five-membered boric acid compounds having a structure represented by a formula shown in the description shows that the compounds have a proteasome inhibition effect, and can be further used for preparing medicines for treating proteasome correlated diseases.